

# TEXAS ACADEMY OF FAMILY PHYSICIANS

## *Disclosure Policy and Implementation*

This policy is to provide guidance for all individuals involved in planning TAFP CME activities on the ACCME disclosure requirements.

TAFP requires the following individuals to complete the TAFP Disclosure Form: TAFP's planning committee, member of the Commission on Annual Session and CME, members of the staff of TAFP, joint sponsor or cosponsor's staff, speakers, moderators or authors.

- The form shall note the title and date of the activity
- The form shall solicit information about all financial relationships the individual or his/her immediate family has with any commercial supporter as well as manufacturers of products whether or not it relates to the CME activity.
- All parties must disclose any significant relationship between themselves and (a) the commercial supporter(s) of the activity, and (b) the manufacturer of any product discussed in the CME activity or related to the topic of the activity. "Significant relationship" is defined as the receipt of any amount, and includes funds received by the immediate family of the individual.
  - Information reported shall include financial relationships in place over the previous 12-months.
  - Individuals with nothing to disclose are still required to complete TAFP's Disclosure Form.
  - TAFP must disclose to participants, verbally and in writing, the commercial supporter(s) of a CME activity, if applicable. Financial interest is defined as being a shareholder, consultant, grant recipient, research participant, employee, and/or recipient of other financial or material support.
- The form shall inquire as to whether the individual intends to discuss off-label uses of drugs and devices in his or her presentation.
  - Speakers, moderators and authors must disclose to participants, preferably in writing through course materials, if a product under discussion is off label, or if the product is still investigational.
  - Speakers, moderators and authors must present a balanced view of therapeutic options and use only generic names to help foster impartiality. No trade names can be used in the syllabus or slide presentation.

*Approved: March 6, 2010*